Wikipedia

Talk:Steven Grinspoon

Latest comment: 2 days ago by Rusalkii in topic Edits for August 2024
Learn more about this page

Edits for August 2024

edit
Latest comment: 2 days ago5 comments2 people in discussion

I have a conflict of interest as a paid consultant for WhiteHatWiki.com, which was hired by the subject of this article. This page needs significant editing in order to address the issues raised in the warning flag. I plan to do so in more than one post so as not to overwhelm the editor reviewing this request. I will address the problems with the Research section in the next phase. Thank you for reviewing.

1. Please delete the fourth sentence through the tenth sentence in the Lead section. But please keep the eleventh sentence.

Delete:

He has investigated the effects of reduced growth hormone on metabolic dysregulation in obesity and was the first to propose the use of a Growth Hormone-releasing Hormone (GHRH) analogue to increase endogenous GH secretion on lipodystrophy and generalized obesity, which led to the FDA approval of Tesamorelin for excess visceral fat accumulation in HIV-infected patients.[1] This work has now been extended to show effects on non-alcoholic fatty liver disease (NAFLD).[2] More recently, his research focuses on the inflammatory mechanisms by which ectopic fat and other metabolic perturbations contribute to HIV-Cardiovascular disease (CVD), and in this regard, he led the AHA State of the Science Conference on CVD in HIV. Additionally, he is leading the multicenter REPRIEVE study, the first study of a primary prevention strategy for CVD in people living with HIV.[3] He has also investigated increased Renin-Angiotensin-Aldosterone System (RAAS) activation and immune activation in relationship to visceral fat accumulation, and the mechanisms of subcutaneous adipose dysfunction involving DICER. Grinspoon has served on the Harvard faculty since 1995 and has been selected by the American Society for Clinical Investigation and the Association of American Physicians for his scientific contributions.[4][5][6] He received the American Federation of Medical Research Investigator of the Year Award in 2005 and the Edward H. Ahrens Jr. Award for Patient Oriented Research in 2014 as well as the Endocrine Society Laureate Award for Translational Research in 2016.[7][8][9] He has published over 330 articles and mentored over 40 trainees in his career. He was elected as a Member of the American Clinical and Climatological Association for his achievements in 2017.[10] His work demonstrating the effects of Tesamorelin to reduce hepatic fat and fibrosis progression in NAFLD, published in Lancet HIV, was a finalist for the Clinical Research Forum’s top 10 Clinical Research Achievement Awards in 2020.[11][12]

Why: As written, the Lead is excessively long and too highly detailed. The suggested replacement offers a concise overview of the topic and leaves the highly technical information fleshed out in the body of the article.

  Done 17:54, 27 August 2024 (UTC)

2. Please replace the “Publications” section and move beneath the “Research and awards” section, renamed as “Selected works”:

Grinspoon has published 309 original research articles, and over 50 review papers in his field. He has authored key Chapters in the Williams Textbook of Endocrinology and The Oxford textbook of Endocrinology on the endocrine manifestation of HIV/AIDS.[13][14] He has served on the Weight Loss and Wasting Working Group Expert Panel on National HIV/AIDS to develop Nutrition Guidelines for the Department of Health and Human Services and developed guidelines for the Nutritional Assessment of HIV-infected Patients in work commissioned by the NIH and WHO.[15] He has contributed to guidelines on the prevention and management of cardiovascular disease in HIV, Chairing the AHA State of the Science Conference on CVD Risk in HIV in 2008, published in Circulation and the NIH sponsored symposium on the Review and Recognition of Obesity in HIV in 2017, published in Clinical Infectious Diseases[16]. He has also participated in the writing group of guidelines for the International AIDS Society-USA Management of Metabolic Complications Associated with Antiretroviral Therapy for HIV-1 infection.[17] He has served on the Advisory Boards of JCEM, JAIDS AIDS, and Nature Reviews Endocrinology, and the Journal of Clinical Investigation.[citation needed]

Replace with:

“Selected Works”

  • Grinspoon, Steven K. (April 2003). "Weight loss and wasting in patients infected with human immunodeficiency virus.” Clinical Infectious Diseases 36 (69-78).[18]
  • Grinspoon, Steven K. (19 June 2008). “Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS”.Circulation (journal) 18[19]
  • Grinspoon, Steven K. ;Lake, Jordan, Stanley, Takara; Apovian, Caroline; Brown, Todd. (15 May 2017). “Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus Infection”. Clinical Infectious Diseases 64 (1422–1429).[20]
  • Grinspoon, Steven K; Brown, Todd T. (2020) Williams Textbook of Endocrinology:”Endocrinology of HIV/AIDS”. Elsevier.[21]
  • Grinspoon, Steven K; Stlanley, Takara L. (January 2022) Oxford Textbook of Endocrinology and Diabetes: “Abnormalities in HIV Infection”. Oxford University Press.[22]
  • Grinspoon, Steven K; Zanni, Markella V.; Fitchenbaum, Carl J. (July 23, 2023) New England Journal of Medicine: “Pitavastatin to Prevent Cardiovascular Disease in HIV Infection”. Massachusetts Medical Society.[23]

Why: The existing section is missing citations and contains WP:OR (“Grinspoon has published 309 original research articles, and over 50 review papers in his field.”) The suggested replacement lists Grinspoon’s published works in publications that meet WP:MEDRS. I’ve suggested changing the section title and formatting to mirror the structure of similar pages.

  Done Mixed feelings here. I generally don't love when there's just a list of publications without any context whatsoever, and high-quality articles generally avoid this. However, the current content isn't great, and most of the important information here can be covered under research. 18:06, 27 August 2024 (UTC)

3. Please replace the first paragraph of the “Education” section:

Change from:

Grinspoon graduated from Cornell University in 1983, attended the University of Rochester School of Medicine, graduating in 1988, and was awarded AOA Alumni Award from the medical school in 2006.[citation needed] He did his medical residency and Chief Residency at Columbia Presbyterian from 1988 to 1992 and his Endocrinology Fellowship at Massachusetts General Hospital from 1992 to 1995.[5]

Change to:

Grinspoon graduated from Cornell University in 1983.[24] He attended the University of Rochester School of Medicine, graduating in 1988.[25] He did his medical residency and Chief Residency at Columbia Presbyterian from 1988 to 1992 and his Endocrinology Fellowship at Massachusetts General Hospital from 1992 to 1995.[5]

Why: The suggested revision includes citations for his degrees that are currently missing. I’ve also suggested removing the AOA Alumni Award because it’s unsourced and is probably promo.

  Done Rusalkii (talk) 18:06, 27 August 2024 (UTC)Reply

4. Please replace the “Awards” subsection under the “Research and awards” section.

Change from:

Grinspoon was elected to the American Society of Clinical Investigation (ASCI) in 2003 and the Honor Society for Humanism in Medicine for the Arnold P. Gold Foundation in 2004. He received the Outstanding Investigator Award from the American Federation for Medical Research in 2005 and was honored with the Pfizer Visiting Professorship at UC Davis in 2004, the Frank H. Tyler Honorary Endowed Lectureship at the University of Utah in 2008, the Dorothy M. Kahkonen Lectureship at the Henry Ford Health System in 2009, the Johnson Maguire Visiting Professorship at the University of Cincinnati in 2015 and the Michael O. Thorner Distinguished Lectureship in Endocrinology from the University of Virginia in 2019. He was named the Alpha Omega Alpha Alumni of the year Awardee at the University of Rochester in 2006 and elected to the Association of American Physicians in 2011. In 2014, he received the Edward H. Ahrens Award for Patient Oriented Clinical Research from the Association of Clinical and Translational Science (ACTS) and the American Medical Federation for Medical Research (AMFAR). In 2016 He received the Gerald Aurbach Laureate Award[26] for Outstanding Translational Research from the Endocrine Society. In 2017 he was elected to the American Clinical and Climatological Association. Grinspoon received an Albert Nelson Lifetime Achievement Award from Who’s Who in America in 2017 and his research on the use of Tesamorelin for fatty liver disease in the Lancet HIV was named as a finalist to the Top 10 Clinical Research Achievement Awards[27] in 2020. In 2023, he was named the 2023 Berson-Yalow Lecturer for the Mt. Sinai Department of Medicine.

Change to:

Grinspoon was elected to the American Society for Clinical Investigation in 2003.[28]

In 2016, he received the Gerald D. Aurbach Laureate Award for Outstanding Translational Research from the Endocrine Society.[26]

Why: The current subsection is excessively long and detailed. As written, it reads more like a CV than an encyclopedic entry. The suggested replacement removes all unsourced awards as well as those that don’t have a Wikipedia page. I’ve suggested including the two awards that have Wikipedia pages and can be verified through reliable sources.

  Done Rusalkii (talk) 18:08, 27 August 2024 (UTC)Reply

5. Please delete the “Key discoveries” subsection under the “Research and awards” section:

“Key discoveries”

  • Efficacy of Tesamorelin to reduce visceral adiposity 2007 (NEJM)[29]
  • Efficacy of Tesamorelin to reduce liver fat 2014 (JAMA)[8]
  • Efficacy of Tesamorelin to prevent liver fibrosis progression in 2019 (Lancet HIV)[9]
  • Demonstration of Tesamorelin effects on key hepatic metabolic pathways in 2020 (JCI Insight)[10]
  • Demonstration of increased arterial inflammation in HIV in 2012 (JAMA)[30]
  • Identification of key genes and proteins leading to dysfunctional subcutaneous adipose tissue in HIV Lipodystrophy 2021 (JCI Insight)
  • First use of macrophage specific imaging agent to identify plaque cardiovascular imaging (JID 2021)

Why: Key Discoveries is WP:OR as nothing in the sources supports the designation of “key discovery.” Furthermore, two of the items are unsourced. Those that are sourced already appear in the “Research” section so they’re inclusion here is redundant.

  Done Rusalkii (talk) 17:54, 27 August 2024 (UTC)Reply

6. Please delete the “Selected talks” subsection under the “Research and awards” section.

Why: None of the information is supported by a source. And it’s all Promo.

  Done Rusalkii (talk) 17:54, 27 August 2024 (UTC)Reply

Thank you for reviewing these proposals.

  1. ^ Wass, John A. H.; Stewart, Paul M. (2011-07-28). Oxford Textbook of Endocrinology and Diabetes. OUP Oxford. ISBN 978-0-19-923529-2.
  2. ^ "Nutrient requirements for people living with HIV/AIDS: Report of a technical consultation" (PDF). World Health Organization. Archived (PDF) from the original on June 24, 2006. Retrieved 7 April 2021.
  3. ^ Lake JE, Stanley TL, Apovian CM, Bhasin S, Brown TT, Capeau J, Currier JS, Dube MP, Falutz J, Grinspoon SK, Guaraldi G, Martinez E, McComsey GA, Sattler FR, Erlandson KM. Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus Infection. Clin Infect Dis. 2017 May 15;64(10):1422-1429. doi:10.1093/cid/cix178 Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1431-1433. PMID 28329372; PMCID: PMC5411395.
  4. ^ Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS; International AIDS Society-USA. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):257-75. doi:10.1097/00126334-200211010-00001 PMID 12439201.
  5. ^ a b c "Steven Grinspoon, MD - Neuroendocrinology". Massachusetts General Hospital. Retrieved 2021-04-07.
  6. ^ Falutz, Julian; Allas, Soraya; Blot, Koenraad; Potvin, Diane; Kotler, Donald; Somero, Michael; Berger, Daniel; Brown, Stephen; Richmond, Gary; Fessel, Jeffrey; Turner, Ralph (2007-12-06). "Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV". New England Journal of Medicine. 357 (23): 2359–2370. doi:10.1056/NEJMoa072375. ISSN 0028-4793. PMID 18057338.
  7. ^ Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, Hemphill L, Lee H, Grinspoon S. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA. 2008 Aug 6;300(5):509-19. doi:10.1001/jama.300.5.509 PMID 18677023; PMCID: PMC2532757.
  8. ^ a b Cite error: The named reference :10 was invoked but never defined (see the help page).
  9. ^ a b Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, Aepfelbacher J, Buckless C, Tsao A, Kellogg A, Branch K, Lee H, Liu CY, Corey KE, Chung RT, Torriani M, Kleiner DE, Hadigan CM, Grinspoon SK. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019 Dec;6(12):e821-e830. doi:10.1016/S2352-3018(19)30338-8 Epub 2019 Oct 11. PMID 31611038; PMCID: PMC6981288.
  10. ^ a b Fourman LT, Billingsley JM, Agyapong G, Ho Sui SJ, Feldpausch MN, Purdy J, Zheng I, Pan CS, Corey KE, Torriani M, Kleiner DE, Hadigan CM, Stanley TL, Chung RT, Grinspoon SK. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight. 2020 Aug 20;5(16):e140134. doi:10.1172/jci.insight.140134 PMID 32701508; PMCID: PMC7455119.
  11. ^ Cite error: The named reference :2 was invoked but never defined (see the help page).
  12. ^ Cite error: The named reference :3 was invoked but never defined (see the help page).
  13. ^ Cite error: The named reference :5 was invoked but never defined (see the help page).
  14. ^ Cite error: The named reference :6 was invoked but never defined (see the help page).
  15. ^ Cite error: The named reference :7 was invoked but never defined (see the help page).
  16. ^ Cite error: The named reference :8 was invoked but never defined (see the help page).
  17. ^ Cite error: The named reference :9 was invoked but never defined (see the help page).
  18. ^ Grinspoon, Steven K.; Mulligan, Kathleen (April 2003). "Department of Health and Human Services Working Group on the Prevention and Treatment of Wasting and Weight Loss. Weight loss and wasting in patients infected with human immunodeficiency virus". Clinical Infectious Diseases. doi:10.1086/367561. PMID 12652374. Retrieved 1 July 2024.
  19. ^ Grinspoon, Steven K.; et, al (19 June 2008). "State of the Science Conference: Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS: Executive Summary". Circulation. 18. doi:10.1161/CIRCULATIONAHA.107.18962. Retrieved 25 July 2024.
  20. ^ Lake, Jordan; Stanley, Takara; Apovian, Caroline; Brown, Todd; Grinspoon, Steven (15 May 2017). "Practical Review of Recognition and Management of Obesity and Lipohypertrophy in Human Immunodeficiency Virus Infection". Clinical Infectious Diseases. 64 (10): 1422–1429. doi:10.1093/cid/cix178. Retrieved 24 July 2024.
  21. ^ Grinspoon, Steven K.; Brown, Todd T. (2020). Williams Textbook of Endocrinology:”Endocrinology of HIV/AIDS”. Elsevier. ISBN 978-0-323-55596-8.
  22. ^ Grinspoon, Steven K.; Stanley, Takara L. (January 2022). Oxford Textbook of Endocrinology and Diabetes (3 ed.). Oxford University Press. p. 1715–1724. ISBN 9780191840739.
  23. ^ Grinspoon, Steven K.; Fitch, Kathleen D.; Zanni, Markella V.; Fitchenbaum, Carl J. (23 July 2023). "Pitavastatin to Prevent Cardiovascular Disease in HIV Infection". New England Journal of Medicine. 389. doi:10.1056/NEJMoa2304146. Retrieved 1 August 2024.
  24. ^ "Steven Kyle Grinspoon, M.D." Harvard.edu. Retrieved 1 July 2024.
  25. ^ "Miss Sandler Married To Dr. S. K. Grinspoon". New York Times. 5 June 1988. Retrieved 1 July 2024.
  26. ^ a b Newman, Mark (2016-01-22). "Meet the 2016 Laureate Award Winners: Steven Grinspoon, MD". Endocrine News. Retrieved 2022-10-17.
  27. ^ "2020 TOP 10 FINALISTS".
  28. ^ "The American Society for Clinical Investigation". the-asci.org. Retrieved 1 July 2024.
  29. ^ Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007 Dec 6;357(23):2359-70. doi:10.1056/NEJMoa072375 PMID 18057338.
  30. ^ Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, Corsini E, Abdelbaky A, Zanni MV, Hoffmann U, Williams KC, Lo J, Grinspoon SK. Arterial inflammation in patients with HIV. JAMA. 2012 Jul 25;308(4):379-86. doi:10.1001/jama.2012.6698 PMID 22820791; PMCID: PMC3724172.

Brucemyboy1212 (talk) 18:38, 12 August 2024 (UTC)Reply

Add topic
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Steven_Grinspoon&oldid=1242606286"